Increasing pressure on drugmakers to ease their drug pricing strategies has led a not only less-frequent price hikes, but also less significant increases, according to a Leerink analysis. According to an Endpoint News report, the analysis included 17 biopharmaceutical companies, including AbbVie, […]
2019 Could Spell Change for Pharma with Democratic House
While the pharmaceutical industry has been mostly untouched in the Trump administration's first 22 months, according to an MM&M report, a new Democratic House and shifting political landscape could mean change is on the horizon. Though little action has been taken against the industry, per the […]
Proposal to Require Drug Prices in Ads Garners Opposition
The government's proposal that would require drugmakers to include a drug's list prices in television ads has drawn opposition from some, including the Association of National Advertisers (ANA) and two academics, FiercePharma reports. The ANA in a blog post and the academics in a New England […]
New Bipartisan Drug Pricing Bill Targets Bad Rebate Practices
A new bipartisan bill introduced by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Oregon) looks to tighten regulations around Medicaid rebates to stop drugmakers from overcharging U.S. taxpayers, The Hill reports. The proposed legislation would provide the Department of Health and Human Services […]
Report: Pharma, U.K. Reach Deal on Pricing, Access
The U.K. government and pharma have reportedly reached a deal to improve market access and broaden efforts to encourage innovation, STAT reports. According to the report, the agreement would deploy spending caps on brand drugs, as well as measures to speed up cost-effectiveness assessments. The […]
AveXis Stands By High Cost, One-Time SMA Therapy
AveXis President Dave Lennon is standing behind the company's high-cost, once-and-done SMA therapy, AVXS-101. According to an Endpoint News report, Lennon said the treatment could be justifiably priced between $4 million and $5 million. "Four million dollars is a significant amount of money, but […]
AstraZeneca CEO: Company Back on Course for Long-term Growth
AstraZeneca is forecasting long-term growth following a bumpy road involving the expiration of key patents, Pascal Soriot, the company’s chief executive, reportedly said during a conference call. Product sales, according to a pharmaphorum report, were reported to have increased 9 percent to some […]
HHS Plans to Implement 340B Final Rule in January
The Department of Health and Human Services plans to implement a long-delayed 340B rule that would set price caps and monetary penalties in the 340B program, FierceHealthcare reports. According to the report, HHS issued a notice, saying the rule would be implemented at the start of the year on Jan. […]
PhRMA CEO Talks DTC Advertising
On the heels of recent moves in the Trump administration to require list prices in direct-to-consumer advertisements for drugs, PhRMA President and CEO Stephen J. Ubl discussed how member companies are planning to move forward. PhRMA says including list prices in advertisements could potentially […]
Orphan Drugs: European Payer Perspectives
Via FirstWord European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and value. Pharma has a trust issue with payers, so how can the industry get back on track and gain European payer support for the expanding orphan drug sector? Payers […]
